



Patent
239/102

REMARKS

The Examiner has required restriction to one of seven groups of claims. Applicant hereby elects, with traverse, to prosecute the claims of group I in this application (*i.e.*, claims 1-4 and 6 drawn to a method of preparing a pharmaceutical composition for stimulating T cells comprising treating target diseased cell to increase levels of one or more primary and costimulatory molecules and said composition comprising an autologous diseased target cell and bridge molecule classified in class 424, subclasses 136.1 and 93.7). In order to expedite prosecution and advance the case towards issuance, Applicant has cancelled non-elected claims 5 and 7-22, without prejudice.

The Examiner has also required election of a specific method employing a specific species of bridge molecule and election of a composition comprising a specific species of bridge molecule. In order to expedite prosecution and advance the case towards issuance, Applicant hereby elects the method and composition comprising the CD28:gp55 bispecific antibody bridge molecule.

CONCLUSION

Accordingly, the application is now in condition for allowance and a notice to that effect is respectfully requested. Enclosed is a check which includes the fee for a two-month extension. If the enclosed fee is incorrect, please charge Deposit Account No. 12-2475 for the appropriate amount.

Respectfully submitted,

LYON & LYON LLP

Dated: 14 July 2000

By: CSB
Charles S. Berkman
Reg. No. 38,077

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(619) 552-8400